Sign In
Buy OCGN
$1.21
-0.0100 (-0.82%)
At Close: Jun 12, 2026
MALVERN, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel g
Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up
12:45pm, Tuesday, 27'th Aug 2024
OCGN receives Health Canada's No Objection Letter to begin a phase III study on OCU400 for treating retinitis pigmentosa. Shares rise.
MALVERN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel g
SAN FRANCISCO , Aug. 20, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Ocugen, Inc. investors that the firm is investigating potential legal claims relating to an earnings restatement a
Ocugen Provides Business Update with Second Quarter 2024 Financial Results
06:45am, Thursday, 08'th Aug 2024
Conference Call and Webcast Today at 8:30 a.m. ET Actively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial OCU410 preliminary safety and efficacy data expected later this year Expanded acce
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
06:30am, Monday, 05'th Aug 2024
MALVERN, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel g
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
03:22pm, Friday, 02'nd Aug 2024
MALVERN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines,
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
09:15pm, Wednesday, 31'st Jul 2024
MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines,
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
04:15pm, Wednesday, 31'st Jul 2024
MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines,
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, de
1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid
08:45am, Thursday, 11'th Jul 2024
CRISPR Therapeutics could ride the wave of its first approval to deliver solid performance over the long run. Despite decent clinical progress, Ocugen remains a high-risk play that has yet to show its
3 Penny Stocks That Could Turn $10K Into $100K in 3 Years
06:39am, Saturday, 06'th Jul 2024
Investing in penny stocks can be a gateway to high financial gains, particularly when identifying high-potential opportunities. Here, the spotlight is on three high-potential penny stocks that possess
Ocugen: Paradigm Shift Gene Therapy Facing Cash Flow Hurdles
11:07am, Monday, 01'st Jul 2024
Ocugen's most advanced product candidate, OCU400, has started Phase 3 clinical trials, aiming for regulatory approval in the U.S. and Europe by 2026. The gene therapy platform shows promise in treatin
Is Ocugen (OCGN) Stock Outpacing Its Medical Peers This Year?
10:46am, Monday, 24'th Jun 2024
Here is how Ocugen (OCGN) and Organon (OGN) have performed compared to their sector so far this year.
